公开(公告)号：US20090010932A1

公开(公告)日：2009-01-08

申请号：US12179399

申请日：2008-07-24

Applicant: JACK T. STAPLETON ,  Jinhua Xiang ,  Donna Klinzman ,  James H. McLinden

Inventor： JACK T. STAPLETON ,  Jinhua Xiang ,  Donna Klinzman ,  James H. McLinden

IPC: C07K16/08 ,  A61K39/395 ,  A61K31/7072 ,  A61K31/711 ,  A61K39/29

CPC classification number: A61K39/29 ,  A61K2039/505 ,  C07K14/05 ,  C07K14/1841 ,  C07K16/109 ,  C07K2317/34 ,  C12N7/00 ,  C12N2770/24222 ,  C12N2770/24234

Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.

Abstract translation: GB病毒C（GBV-C或丙型肝炎病毒）是经常导致人类慢性病毒血症的黄病毒。 本发明提供涉及用于抑制和治疗HIV感染的抗GBV-C抗体或其它GBV-C结合剂或GBV-C抗原的组合物和方法。

公开(公告)号：US07439347B2

公开(公告)日：2008-10-21

申请号：US11249893

申请日：2005-10-13

Applicant: Matti Sällberg

Inventor： Matti Sällberg

IPC: A61K39/29 ,  A61L2/00

CPC classification number: A61K39/29 ,  A01K67/0271 ,  A61K31/7056 ,  A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/57 ,  A61K2121/00 ,  A61K2123/00 ,  C07K14/005 ,  C07K16/109 ,  C12N7/00 ,  C12N2740/16134 ,  C12N2770/24022 ,  C12N2770/24221 ,  C12N2770/24222 ,  C12N2770/24234 ,  G06F19/00 ,  G06Q50/22 ,  Y02A50/464 ,  Y02A90/22 ,  Y02A90/26

Abstract: Disclosed herein is the discovery of a novel hepatitis C virus (HCV) isolated from a human patient. Embodiments of the invention include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as, methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.

Abstract translation: 本文公开了从人类患者分离的新型丙型肝炎病毒（HCV）的发现。 本发明的实施方案包括HCV肽，编码所述HCV肽的核酸，针对所述肽的抗体，含有所述核酸和肽的组合物，以及制备和使用上述组合物的方法，包括但不限于诊断和 用于治疗和预防HCV感染的药物。

公开(公告)号：US07407663B2

公开(公告)日：2008-08-05

申请号：US10601656

申请日：2003-06-20

Applicant: Bill E. Cham ,  Jo-Ann B. Maltais

Inventor： Bill E. Cham ,  Jo-Ann B. Maltais

IPC: A61K39/21

CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K39/29 ,  A61K39/292 ,  A61K2039/5252 ,  A61K2039/55566 ,  A61K2039/57 ,  A61L2/0011 ,  A61L2/0088 ,  A61M1/3486 ,  C12N2730/10134 ,  C12N2730/10163 ,  C12N2770/24334 ,  C12N2770/24363

Abstract: The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious organism, thereby reducing the infectivity of the infectious organism. The present invention uses optimal solvent systems such that the lipid envelope around the viral particle is dissolved while the viral particle remains intact, resulting in a modified viral particle. The present invention also provides an autologous vaccine composition, comprising a lipid-containing infectious organism, treated with solvents to reduce the lipid content of the infectious organism, combined with a pharmaceutically acceptable carrier. The vaccine composition is administered to an animal or a human to provide protection against the lipid-containing infectious organism. The present invention further provides a simple, inexpensive and easy to use kit for delipidating fluids and for delipidation of lipid-containing organisms in a fluid.

Abstract translation: 本发明涉及一种降低感染性疾病，特别是生物流体如血液中含有脂质感染性生物的感染性疾病的发生和严重性的方法。 本发明使用可用于从含脂质感染性生物体提取脂质的溶剂，从而降低感染性生物体的感染性。 本发明使用最佳的溶剂体系，使病毒颗粒周围的脂质包膜溶解，同时病毒颗粒保持完整，导致改良的病毒颗粒。 本发明还提供一种自体疫苗组合物，其包含用溶剂处理以降低感染性生物体的脂质含量并与药学上可接受的载体组合的含脂质感染性生物体。 将疫苗组合物施用于动物或人体以提供针对含脂质感染生物的保护。 本发明还提供了一种简单，便宜且易于使用的用于使流体脱脂和用于流体中含脂质生物体的脱脂作用的试剂盒。

公开(公告)号：US20080145915A1

公开(公告)日：2008-06-19

申请号：US11979440

申请日：2007-11-02

Applicant: Ramareddy Venkata Guntaka ,  Chittoor Mohammad Habibullah ,  Mohammad Nanne Khaja ,  Chandra Madhavi

Inventor： Ramareddy Venkata Guntaka ,  Chittoor Mohammad Habibullah ,  Mohammad Nanne Khaja ,  Chandra Madhavi

IPC: C12N7/00 ,  C12N15/51 ,  C07H21/00

CPC classification number: C12N7/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/29 ,  C07K14/005 ,  C12N2770/24221 ,  C12N2770/24222 ,  C12N2770/24234

Abstract: The present invention relates to isolation of a novel Hepatitis C virus, more particularly, the present invention relates to a viral class Hepatitis C, polypeptides, polynucleotide, vaccine and antibodies derived there from.

公开(公告)号：US07374766B1

公开(公告)日：2008-05-20

申请号：US09857402

申请日：1999-12-01

Applicant: Julio César Aguilar Rubido ,  Daniel O. Palenzuela Gardón ,  Verena L. Muzio González ,  Gerardo E. Guillén Nieto ,  Eduardo Pentón Arias ,  Dagmara Pichardo Díaz ,  Enrique Iglesias Perez

Inventor： Julio César Aguilar Rubido ,  Daniel O. Palenzuela Gardón ,  Verena L. Muzio González ,  Gerardo E. Guillén Nieto ,  Eduardo Pentón Arias ,  Dagmara Pichardo Díaz ,  Enrique Iglesias Perez

IPC: A61K39/29 ,  A61K39/00 ,  A61K39/12

CPC classification number: A61K39/29 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55583 ,  A61K2039/57 ,  A61K2039/70 ,  C12N2710/20023 ,  C12N2710/20034 ,  C12N2730/10134

Abstract: The present invention is related to the branch of medicine, particularly to the new formulations of vaccine antigens.The technical objective pursued with the present invention is, precisely, the development of formulations that are able to enhance the immune response to mucosally administered antigens, minimising the number of compounds in the formulation and generating strong mucosal and systemic responses through a synergic interaction between the antigens in the formulation.These formulations enable: a) to broaden the spectrum of the anti-hepatitis B immune response, containing as main compounds HBsAg and HBcAg, b) to enhance the response against HBsAg with a viral nucleocapsid c) to generate combined vaccines through the mucosal route with HBsAg as a central antigen. Stabilizers and preservatives can be introduced.The formulations of this invention can be applied in the pharmaceutical industry as human or veterinary vaccine formulations.

Abstract translation: 本发明涉及药物分支，特别是涉及疫苗抗原的新制剂。 本发明所追求的技术目标正是开发能够增强对粘膜施用抗原的免疫应答的制剂，使制剂中化合物的数量最小化，并通过协同相互作用产生强烈的粘膜和系统反应 制剂中的抗原。 这些配方能够：a）扩大抗乙型肝炎免疫反应的谱，含有主要化合物HBsAg和HBcAg，b）通过病毒核衣壳c）增强对HBsAg的反应c）通过粘膜途径产生组合疫苗， HBsAg作为中枢抗原。 可以引入稳定剂和防腐剂。 本发明的制剂可以作为人或兽用疫苗制剂应用于制药工业。

公开(公告)号：US07329408B2

公开(公告)日：2008-02-12

申请号：US09728423

申请日：2000-12-01

Applicant: Michael Houghton ,  Mark Selby ,  Sergio Abrignani ,  Jens Martin Heile ,  Derek O'Hagan

Inventor： Michael Houghton ,  Mark Selby ,  Sergio Abrignani ,  Jens Martin Heile ,  Derek O'Hagan

IPC: A61K39/29

CPC classification number: C07K14/005 ,  A61K9/167 ,  A61K31/7088 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/57 ,  C12N2770/24222 ,  C12N2770/24234

Abstract: Described herein is a method of eliciting antibodies and neutralizing of binding antibodies against a hepatitis C virus (HCV) E1E2 or E2 antigen using HCV E2 or HCV E1E2 polypeptides and/or HCV E2 or E1E2 polynucleotides. Elicitation of anti-E2 antibodies and anti-E2 NOB antibodies can be used, inter alia, to provide model systems to optimize anti-E2 antibody responses and/or anti-E2 NOB antibody responses to HCV and to provide prophylactic or therapeutic treatment against HCV infection.

Abstract translation: 本文描述的是使用HCV E2或HCV E1E2多肽和/或HCV E2或E1E2多核苷酸引发抗体并中和针对丙型肝炎病毒（HCV）E1E2或E2抗原的结合抗体的方法。 可以使用抗E2抗体和抗E2 NOB抗体的引发，以提供模型系统来优化抗E2抗体应答和/或抗HCV NOB抗体对HCV的反应，并提供针对HCV的预防或治疗性治疗 感染。

公开(公告)号：US07307066B2

公开(公告)日：2007-12-11

申请号：US11043808

申请日：2005-01-25

Applicant: Matti Sallberg

Inventor： Matti Sallberg

IPC: A61K48/00 ,  A61K35/00

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/29 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/57 ,  A61K2121/00 ,  A61K2123/00 ,  C12N7/00 ,  C12N2730/10134 ,  C12N2770/24022 ,  C12N2770/24221 ,  C12N2770/24222 ,  C12N2770/24234 ,  C12N2800/22 ,  Y02A90/22 ,  Y02A90/26 ,  A61K2300/00

Abstract: Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.

Abstract translation: 本发明的方面涉及新型丙型肝炎病毒（HCV）分离株的发现。 实施方案包括HCV肽，编码所述HCV肽的核酸，针对所述肽的抗体，含有所述核酸和肽的组合物，以及制备和使用上述组合物的方法，包括但不限于用于治疗的诊断和药物 并预防HCV感染。

公开(公告)号：US20070160631A1

公开(公告)日：2007-07-12

申请号：US10524936

申请日：2003-08-12

Applicant: David Jackson ,  Weiguang Zeng

Inventor： David Jackson ,  Weiguang Zeng

IPC: A61K39/145 ,  C07K14/775

CPC classification number: A61K39/39 ,  A61K39/07 ,  A61K39/12 ,  A61K39/145 ,  A61K39/29 ,  A61K39/385 ,  A61K2039/5158 ,  A61K2039/55516 ,  A61K2039/55544 ,  A61K2039/55566 ,  A61K2039/57 ,  A61K2039/6018 ,  A61K2039/6031 ,  A61K2039/6037 ,  A61K2039/6075 ,  C07K14/005 ,  C07K14/195 ,  C07K19/00 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/18422 ,  C12N2770/24222 ,  C12N2770/24234

Abstract: The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular CTL epitopes. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the CTL epitope.

Abstract translation: 本发明提供了包含共线T-辅助和CTL表位的合成的免疫原性脂肽分子，及其生产和用于产生初级和次级免疫应答的方法，以及针对特定CTL表位的动物受试者的疫苗接种。 更具体地，本发明提供高可溶性脂肽，其中脂质部分连接到内部赖氨酸或赖氨酸类似物的末端侧链基团，优选连接到内部二氨基酸残基的末端侧链基团。 优选地，内部赖氨酸或赖氨酸类似物位于T辅助表位和CTL表位之间。

公开(公告)号：US20070116714A1

公开(公告)日：2007-05-24

申请号：US11613797

申请日：2006-12-20

Applicant: Moncef Slaoui ,  Pierre Hauser

Inventor： Moncef Slaoui ,  Pierre Hauser

IPC: A61K39/295

CPC classification number: A61K39/092 ,  A61K39/0016 ,  A61K39/04 ,  A61K39/05 ,  A61K39/08 ,  A61K39/095 ,  A61K39/099 ,  A61K39/102 ,  A61K39/12 ,  A61K39/13 ,  A61K39/29 ,  A61K39/292 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/70 ,  C12N2730/10134 ,  C12N2770/32634 ,  Y02A50/464 ,  Y02A50/466

Abstract: The present invention relates to combination vaccines comprising a conjugated polysaccharide antigen linked to a carrier protein, and wherein the carrier protein is also present as a free antigen in the vaccine composition, characterised in that the ratio of polysaccharide to protein is from 1:0:3 to 1:2. In particular, the vaccine composition of the present invention relates to a multivalent vaccine, that is a vaccine for the amelioration or treatment of more than one disease state. The present invention also relates to the production and use of such a vaccine in medicine.

Abstract translation: 本发明涉及包含与载体蛋白连接的共轭多糖抗原的组合疫苗，并且其中载体蛋白质也作为疫苗组合物中的游离抗原存在，其特征在于多糖与蛋白质的比例为1:0:2 3比1：2。 特别地，本发明的疫苗组合物涉及多价疫苗，其是用于改善或治疗多于一种疾病状态的疫苗。 本发明还涉及这种疫苗在医药中的生产和使用。

公开(公告)号：US07147862B1

公开(公告)日：2006-12-12

申请号：US08909879

申请日：1997-08-12

Applicant: Jean-Paul Prieels ,  Nathalie Marie-Josephe Claude Garcon-Johnson ,  Moncef Slaoui ,  Pietro Pala

Inventor： Jean-Paul Prieels ,  Nathalie Marie-Josephe Claude Garcon-Johnson ,  Moncef Slaoui ,  Pietro Pala

IPC: A61K39/21 ,  A61K45/00

CPC classification number: A61K39/292 ,  A61K39/015 ,  A61K39/12 ,  A61K39/245 ,  A61K39/29 ,  A61K39/39 ,  A61K2039/55505 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/57 ,  C12N2710/16634 ,  C12N2730/10134 ,  Y02A50/412 ,  Y02A50/464

Abstract: The present invention provides vaccine compositions comprising 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccines compositions are potent inducers of CTL and γ IFN responses.

Abstract translation: 本发明提供包含3个De-O-酰化单磷酰脂质A和QS21的疫苗组合物。 疫苗组合物是CTL和γIFN应答的有效诱导剂。